Clovis study: Rubraca improves chances for ovarian cancer patients with BRCA mutation

Clovis study: Rubraca improves chances for ovarian cancer patients with BRCA mutation

BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) announced data from the randomized, Phase 3 ARIEL4 study of Rubraca ® (rucaparib) demonstrate that Rubraca significantly improves PFS compared to... Read More

Tuesday March 23, 2021 0 comments Tags: Boulder, Clovis Oncology, Rubraca, Patrick J. Mahaffy

Clovis Oncology submits Investigational New Drug applications to FDA for FAP-2286 for therapeutic and imaging clinical trial

Clovis Oncology submits Investigational New Drug applications to FDA for FAP-2286 for therapeutic and imaging clinical trial

BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced it has completed submission of two Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA) for... Read More

Tuesday December 29, 2020 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffy, FAP-2286, FDA

Clovis Oncology: Rubraca meets primary endpoint of significantly improving progression-free survival vs. chemo in cancer study

Clovis Oncology: Rubraca meets primary endpoint of significantly improving progression-free survival vs. chemo in cancer study

BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS), today announced topline data from the randomized Phase 3 ARIEL4 study of Rubraca, which met its primary endpoint of improved investigator-assessed... Read More

Monday December 21, 2020 0 comments Tags: Boulder, Clovis Oncology, Rucaparib, Rubraca, Patrick J. Mahaffy

Clovis Oncology announces purchase of additional $7.5M of its 4.50% convertible senior notes due 2024

Clovis Oncology announces purchase of additional $7.5M of its 4.50% convertible senior notes due 2024

BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) announced an existing holder of its securities relating to the offering of the company’s new series of 4.50% Convertible Senior Notes due 2024 has... Read More

Wednesday November 25, 2020 0 comments Tags: Boulder, Clovis Oncology, Rucaparib

Clovis: FDA approves FoundationOne Liquid CDx to serve as Rubraca companion diagnostic to identify eligible patients with BRCA1/2-mutant, metastatic castration-resistant prostate cancer

Clovis: FDA approves FoundationOne Liquid CDx to serve as Rubraca companion diagnostic to identify eligible patients with BRCA1/2-mutant, metastatic castration-resistant prostate cancer

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced the U.S. Food and Drug Administration approved the FoundationOne ® Liquid CDx, Foundation Medicine’s comprehensive liquid biopsy test... Read More

Friday August 28, 2020 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffy, Rubraca

Clovis Oncology: First patient enrolled in Phase 2  of LIO-1 trial evaluating pairing Lucitanib, Opdivo

Clovis Oncology: First patient enrolled in Phase 2  of LIO-1 trial evaluating pairing Lucitanib, Opdivo

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) today announced treatment of the first patient in the Phase 2 portion of the LIO-1 trial evaluating the combination of lucitanib, Clovis’... Read More

Wednesday August 5, 2020 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffy

Clovis Oncology to highlight Rubraca and Lucitanib non-clinical data at AACR virtual annual meeting June 22-24

Clovis Oncology to highlight Rubraca and Lucitanib non-clinical data at AACR virtual annual meeting June 22-24

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) today announced four abstracts showcasing non-clinical data from rucaparib and lucitanib development programs have been accepted for on-demand... Read More

Wednesday June 17, 2020 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffy, Rubraca, Lucitanib

Clovis Oncology announces completion of target enrollment in Phase 3 ATHENA trial

Clovis Oncology announces completion of target enrollment in Phase 3 ATHENA trial

BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) announced the completion of target patient enrollment in the Clovis-sponsored Phase 3 ATHENA trial evaluating the combination of Clovis’ Rubraca ... Read More

Thursday June 11, 2020 0 comments Tags: Boulder, Clovis Oncology, Patrick J. Mahaffy, Rubraca